News Taiho snaps up ADC partner Araris for up to $1.14bn Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.
News AbbVie builds the case for ovarian cancer drug Elahere AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.
News Sutro puts lead ADC on hold, cuts staff and changes CEO Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.
News Third indication beckons for Amgen's Uplizna Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.
News Insilico raises $110m for AI-designed drug pipeline Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery operations.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.